Abstract: Described are a low temperature plasma reaction device and a hydrogen sulfide decomposition method. The reaction device includes: a first cavity; a second cavity, the second cavity being embedded inside or outside the first cavity; an inner electrode, the inner electrode being arranged in the first cavity; an outer electrode; and a barrier dielectric arranged between the outer electrode and the inner electrode. The hydrogen sulfide decomposition method includes: implementing dielectric barrier discharge at the outer electrode and the inner electrode of the low temperature plasma reaction device, introducing a raw material gas containing hydrogen sulfide into the first cavity to implement a hydrogen sulfide decomposition method, and continuously introducing a thermally conductive medium into the second cavity in order to control the temperature of the first cavity of the low temperature plasma reaction device.

Abstract: Described are a low temperature plasma reaction device and a hydrogen sulfide decomposition method. The reaction device includes: a first cavity; a second cavity, the second cavity being embedded inside or outside the first cavity; an inner electrode, the inner electrode being arranged in the first cavity; an outer electrode; and a barrier dielectric arranged between the outer electrode and the inner electrode. The hydrogen sulfide decomposition method includes: implementing dielectric barrier discharge at the outer electrode and the inner electrode of the low temperature plasma reaction device, introducing a raw material gas containing hydrogen sulfide into the first cavity to implement a hydrogen sulfide decomposition method, and continuously introducing a thermally conductive medium into the second cavity in order to control the temperature of the first cavity of the low temperature plasma reaction device.

Abstract: A method for generating an exam is disclosed. The method includes setting initial conditions for the exam, wherein the initial conditions comprises a number of true propositions p, a number of false propositions q, and a number of random propositions r, and determining numbers of different propositions in the exam according to the initial conditions. The method further includes selecting the p number of true propositions, and numbering each of the p number of true propositions with a running number, selecting q number of false propositions, grouping the q number of false propositions, numbering each of the groups with a group number, selecting the r number of propositions, grouping the r number of propositions, numbering each of the groups with a group number. The method further includes generating an exam according to the p number of true propositions, the q number of false propositions, and the r number of propositions.

Abstract: A method for generating an exam is disclosed. The method includes setting initial conditions for the exam, wherein the initial conditions comprises a number of true propositions p, a number of false propositions q, and a number of random propositions r, and determining numbers of different propositions in the exam according to the initial conditions. The method further includes selecting the p number of true propositions, and numbering each of the p number of true propositions with a running number, selecting q number of false propositions, grouping the q number of false propositions, numbering each of the groups with a group number, selecting the r number of propositions, grouping the r number of propositions, numbering each of the groups with a group number. The method further includes generating an exam according to the p number of true propositions, the q number of false propositions, and the r number of propositions.

Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.

Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.